Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #31
    @melop: It is still not clear if you have talked with the facility about your data/concerns and what the result of that conversation was? Do you know if they contacted Illumina tech support about this run?

    Based on your post in #29 it seems that other 6 lanes on this flowcell were very close to acceptable spec (Illumina spec only specifies 75% bases > Q30 for 2 x 150bp, which seems to refer to entire sequence output from that flowcell).

    It is certainly possible that Illumina refused to provide free replacements. As with any customer service issue the kind of response one gets (in this case free replacements) may entirely depend on the support person you reach.

    Ultimately your result may be due the characteristic of the library. A re-run may produce a very similar result. Only option then would be to remake the library and try again.
    Last edited by GenoMax; 01-27-2016, 09:46 AM.

    Comment

    • melop
      Member
      • Jan 2012
      • 22

      #32
      Originally posted by GenoMax View Post
      @melop: It is still not clear if you have talked with the facility about your data/concerns and what the result of that conversation was? Do you know if they contacted Illumina tech support about this run?

      Based on your post in #29 it seems that other 6 lanes on this flowcell were very close to acceptable spec (Illumina spec only specifies 75% bases > Q30 for 2 x 150bp, which seems to refer to entire sequence output from that flowcell).

      It is certainly possible that Illumina refused to provide free replacements. As with any customer service issue the kind of response one gets (in this case free replacements) may entirely depend on the support person you reach.

      Ultimately your result may be due the characteristic of the library. A re-run may produce a very similar result. Only option then would be to remake the library and try again.
      Yes, they said they will rerun if illumina replaces the reagent for them. They did not say what happens if not. But from the message they seemed to imply that rerunning is contingent upon their success in the negotiations. They stopped replying to our emails after that.

      Comment

      • GenoMax
        Senior Member
        • Feb 2008
        • 7142

        #33
        That is unfortunate. If they don't intend to re-run your samples for free (due to not getting free replacements) then they should have informed you.

        Since they made the libraries this is one of those tough situations (for them, in terms of cost) where they should at least do something to retain your business (either re-run the current libraries to see if the problem recurs or remake the libraries for free but then charge you for running them, only if the new data looks good).
        Last edited by GenoMax; 01-27-2016, 11:05 AM.

        Comment

        • NextGenSeq
          Senior Member
          • Apr 2009
          • 482

          #34
          Originally posted by melop View Post
          Dear all. I'm an end user. Recently we got 2 HiSeq 4000 lanes from a local sequencing facility (150bp x 2 reads), PCR-free gDNA libraries made at the same facility. The quality looks quite bad, especially in read 2, only 60% and 70% of bases >Q30, which doesn't pass the Illumina specs. In this case, is it a common practice for the facility to redo the sequencing for us? We ask because it sounded like they don't want to redo it for us... How about the policy at your sequencing core?
          Illumina will almost always send replacement reagents if you use a small amount of spike-in PhiX sequenced with your library AND the PhiX did not give good sequencing results. If the PhiX gives good sequencing results the problem is the library not the instrument. If both give poor results it is likely an instrument or reagent problem.

          If the sequencing facility did not do this they are amateurs and you shouldn't use them again.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          25 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          19 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          26 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          38 views
          0 reactions
          Last Post SEQadmin2  
          Working...